Ocera Therapeutics Inc news

   Watch this stock
Showing stories 1 - 10 of about 78   

Articles published

OCRX 3.60 -0.17 (-4.51%)
price chart
Gaurav Aggarwal Paid for 7500 Shares of Ocera Therapeutics Inc (NASDAQ ...
Mr. Gaurav Aggarwal, the current Chief Business Officer at Ocera Therapeutics Inc (NASDAQ:OCRX) 3.86 -0.02 -0.52% has a few days ago been connected with a stock market deal of 7,500 shares of the -listed company, valued at $3.6 per share.
Ocera Therapeutics CEO Linda S. Grais Buys 30000 Shares (OCRX)  The Legacy
Gaurav Aggarwal Acquires 7500 Shares of Ocera Therapeutics Stock (OCRX)  sleekmoney
Ocera Therapeutics Finally Ready To Reward Investors
Furthermore, to bluntly state the obvious, Ocera has had a rough 2014. Investors unfamiliar with the company would probably look at the stock chart and move on to the next assuming that something catastrophic had occurred to warrant such a steep price ...
Ocera Therapeutics to Report Pipeline Progress and First Quarter 2015 ...
PALO ALTO, Calif., April 22, 2015 (GLOBE NEWSWIRE) -- Ocera Therapeutics, Inc. (Nasdaq:OCRX), a clinical stage biopharmaceutical company focused on acute and chronic orphan liver diseases, today announced that it will release its first quarter 2015 ...
Ocera Therapeutics to Present at 35th Annual Cowen and Company Health ...
PALO ALTO, Calif., Feb. 23, 2015 (GLOBE NEWSWIRE) -- Ocera Therapeutics, Inc. (Nasdaq:OCRX), a clinical stage biopharmaceutical company focused on acute and chronic orphan liver diseases, today announced that company management will be ...
Ocera Therapeutics to Announce Fourth Quarter and Full Year 2014 Financial ...
PALO ALTO, Calif., March 2, 2015 (GLOBE NEWSWIRE) -- Ocera Therapeutics, Inc. (Nasdaq:OCRX), a clinical stage biopharmaceutical company focused on acute and chronic orphan liver diseases, today announced that it will release its fourth quarter and ...
Ocera Therapeutics Announces Change in Executive Team
PALO ALTO, Calif., May 4, 2015 (GLOBE NEWSWIRE) -- Ocera Therapeutics, Inc. (Nasdaq:OCRX), today announced that Rajiv Patni, M.D.
Ocera Therapeutics Stock Rating Lowered by Zacks (OCRX)
Ocera Therapeutics (NASDAQ:OCRX) was downgraded by Zacks from a “buy” rating to a “hold” rating in a research report issued on Tuesday.
Ocera Therapeutics Downgraded by Zacks (OCRX)  The Legacy
Ocera Therapeutics (OCRX) Reports OCR-002 Phase 2a Missed Primary Endpoint
Ocera Therapeutics, Inc. (Nasdaq: OCRX) today announced preliminary topline results from a Phase 2a investigator-sponsored study evaluating the company's drug candidate OCR-002 (ornithine phenylacetate) versus placebo in patients with upper ...
Ocera sinks on mixed clinical trial results (OCRX)  Seeking Alpha (registration)
Ocera Therapeutics Well-Capitalized After The Merger
Ocera Therapeutics (NASDAQ:OCRX) announced the closing of a merger with Tranzyme on July 15. Immediately following the closing of the merger, certain of the Ocera investors invested approximately $20 million in the company through a private ...
Ocera's lead product clinical trial completion date late 2016 (OCRX)
The Phase 2b study evaluating Ocera Therapeutics' (NASDAQ:OCRX) lead product, OCR-002, for the treatment of hepatic encephalopathy (HE) is scheduled to be completed by H2 2016, based on an increased target enrollment of 230 patients from the ...
Ocera Completes Interim Analysis of OCR-002 in Phase 2b STOP-HE Study for ...  MarketWatch